Trevi Therapeutics, Inc. (TRVI)
NASDAQ: TRVI · Real-Time Price · USD
13.43
-0.77 (-5.42%)
At close: May 18, 2026, 4:00 PM EDT
13.24
-0.19 (-1.41%)
Pre-market: May 19, 2026, 7:00 AM EDT

Trevi Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
17.1615.8512.1510.2410.079.49
Research & Development
35.6133.4839.3823.6819.8322.98
Total Operating Expenses
52.7749.3351.5233.9229.9132.48
Operating Income
-52.77-49.33-51.52-33.92-29.91-32.48
Interest Income
7.116.543.64.751.740.01
Interest Expense
---0-0.39-1.16-1.2
Other Non-Operating Income (Expense)
1.88-0.03-0.020.470.14-0.29
Total Non-Operating Income (Expense)
8.996.513.584.830.72-1.49
Pretax Income
-45.68-42.82-47.94-29.1-29.19-33.96
Provision for Income Taxes
-0.1-0.06-0.030.030.040.02
Net Income
-45.61-42.76-47.91-29.07-29.15-33.94
Net Income to Common
-45.61-42.76-47.91-29.07-29.15-33.94
Shares Outstanding (Basic)
142135102996523
Shares Outstanding (Diluted)
142135102996523
Shares Change (YoY)
33.01%32.14%2.97%53.44%182.56%26.48%
EPS (Basic)
-0.32-0.32-0.47-0.29-0.45-1.49
EPS (Diluted)
-0.32-0.32-0.47-0.29-0.45-1.49
Shares Outstanding
128.41128.3193.668.2859.9428.51
Free Cash Flow
-45.42-42.1-38.29-31.85-28.33-28.95
Free Cash Flow Per Share
-0.32-0.31-0.38-0.32-0.44-1.27
EBITDA
-52.63-49.18-51.38-33.8-29.86-32.43
EBIT
-52.77-49.33-51.52-33.92-29.91-32.48
Effective Tax Rate
0.21%0.15%0.06%-0.11%-0.12%-0.06%
Updated May 5, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q